Search

Your search keyword '"Ikemi, Yasuaki"' showing total 19 results
Start Over Author "Ikemi, Yasuaki"
19 results on '"Ikemi, Yasuaki"'

2. Subjective symptoms are triggers for the detection of immune checkpoint inhibitor-induced interstitial lung disease and associate with disease severity: a single-center retrospective study

Author

Yokoi, Mari, Yonezawa, Atsushi, Hira, Daiki, Handa, Tomohiro, Tanizawa, Kiminobu, Nakagawa, Shunsaku, Tsuda, Masahiro, Ikemi, Yasuaki, Itotani, Ryo, Yoshida, Hironori, Nomura, Motoo, Matsubara, Junichi, Murakami, Kosaku, Ozasa, Hiroaki, Muto, Manabu, and Terada, Tomohiro

Published
2024
Full Text
View/download PDF

6. STAT3 polymorphism associates with mTOR inhibitor-induced interstitial lung disease in patients with renal cell carcinoma

Author

Yamamoto, Kazuhiro, primary, Ioroi, Takeshi, additional, Shinomiya, Kazuaki, additional, Yoshida, Ayaka, additional, Harada, Kenichi, additional, Fujisawa, Masato, additional, Omura, Tomohiro, additional, Ikemi, Yasuaki, additional, Nakagawa, Shunsaku, additional, Yonezawa, Atsushi, additional, Ogawa, Osamu, additional, Matsubara, Kazuo, additional, Iwamoto, Takuya, additional, Nishikawa, Kohei, additional, Hayashi, Sayaka, additional, Tohara, Daichi, additional, Murakami, Yoji, additional, Motoshima, Takanobu, additional, Jono, Hirofumi, additional, and Yano, Ikuko, additional

Published
2022
Full Text
View/download PDF

7. Potential application of measuring serum infliximab levels in rheumatoid arthritis management: A retrospective study based on KURAMA cohort data

Author

Nakae, Kazuto, primary, Masui, Sho, additional, Yonezawa, Atsushi, additional, Hashimoto, Motomu, additional, Watanabe, Ryu, additional, Murata, Koichi, additional, Murakami, Kosaku, additional, Tanaka, Masao, additional, Ito, Hiromu, additional, Yokoyama, Kotoko, additional, Iwamoto, Noriko, additional, Shimada, Takashi, additional, Nakamura, Miyuki, additional, Denda, Masaya, additional, Itohara, Kotaro, additional, Nakagawa, Shunsaku, additional, Ikemi, Yasuaki, additional, Imai, Satoshi, additional, Nakagawa, Takayuki, additional, Hayakari, Makoto, additional, and Matsubara, Kazuo, additional

Published
2021
Full Text
View/download PDF

12. STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma.

Author

Yamamoto, Kazuhiro, Ioroi, Takeshi, Shinomiya, Kazuaki, Yoshida, Ayaka, Harada, Kenichi, Fujisawa, Masato, Omura, Tomohiro, Ikemi, Yasuaki, Nakagawa, Shunsaku, Yonezawa, Atsushi, Ogawa, Osamu, Matsubara, Kazuo, Iwamoto, Takuya, Nishikawa, Kohei, Hayashi, Sayaka, Tohara, Daichi, Murakami, Yoji, Motoshima, Takanobu, Jono, Hirofumi, and Yano, Ikuko

Subjects
RENAL cell carcinoma, EVEROLIMUS, FIBRONECTINS, STAT proteins, KIDNEY diseases, JAPANESE people, MTOR inhibitors, INTERSTITIAL lung diseases
Abstract

We evaluated the association of signal transducer and activator of transcription 3 (STAT3) polymorphisms with the incidence of mammalian target of rapamycin (mTOR) inhibitor-induced interstitial lung disease (ILD) in patients with renal cell carcinoma (RCC). We also used lung-derived cell lines to investigate the mechanisms of this association. Japanese patients with metastatic RCC who were treated with mTOR inhibitors were genotyped for the STAT3 polymorphism, rs4796793 (1697C/G). We evaluated the association of the STAT3 genotype with the incidence of ILD and therapeutic outcome. In the 57 patients included in the primary analysis, the ILD rate within 140 days was significantly higher in patients with the GG genotype compared with those with other genotypes (77.8% vs. 23.1%, odds ratio=11.67, 95% confidential interval=3.0644.46). There were no significant differences in progression-free survival or time-to-treatment failure between the patients with the GG genotype and those with other genotypes. An in vitro study demonstrated that some lung-derived cell lines carrying the GG genotype exhibited an increase in the expression of mesenchymal markers, such as fibronectin, N-cadherin, and vimentin, and decreases in E-cadherin, which is an epithelial marker associated with exposure to everolimus, although STAT3 expression and activity were not related to the genotype. In conclusion, the GG genotype of the STAT3 rs4796793 polymorphism increases the risk of mTOR inhibitor-induced ILD, supporting its use as a predictive marker for RCC. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

13. Analysis of Glycoforms and Amino Acids in Infliximab and a Biosimilar Product Using New Method with LC/TOF-MS

Author

Tsuda, Masahiro, primary, Otani, Yuki, additional, Yonezawa, Atsushi, additional, Masui, Sho, additional, Ikemi, Yasuaki, additional, Denda, Masaya, additional, Sato, Yuki, additional, Nakagawa, Shunsaku, additional, Omura, Tomohiro, additional, Imai, Satoshi, additional, Nakagawa, Takayuki, additional, Hayakari, Makoto, additional, and Matsubara, Kazuo, additional

Published
2018
Full Text
View/download PDF

16. Qualitative Component Analysis of Filgrastim Biosimilars by LC/QTOF-MS

Author

Matsumura, Kengo, primary, Otani, Yuki, additional, Omura, Tomohiro, additional, Yonezawa, Atsushi, additional, Tsuda, Masahiro, additional, Ikemi, Yasuaki, additional, Nakagawa, Shunsaku, additional, Imai, Satoshi, additional, Nakagawa, Takayuki, additional, Yano, Ikuko, additional, Yoshiki, Tatsuhiro, additional, and Matsubara, Kazuo, additional

Published
2016
Full Text
View/download PDF

17. Protocol for Unrequired Inquiries about the Prescription to Doctors under the Agreement between the Hospital and Community Pharmacies

Author

Sakurai, Kaori, primary, Ozaki, Junko, additional, Yano, Ikuko, additional, Adachi, Koichiro, additional, Kimura, Yoshihiko, additional, Matsumura, Katsuyuki, additional, Nishiwaki, Fuki, additional, Yoshida, Yuko, additional, Ikemi, Yasuaki, additional, Kayano, Yuichiro, additional, Yonezawa, Atsushi, additional, Fukatsu, Sachio, additional, and Matsubara, Kazuo, additional

Published
2016
Full Text
View/download PDF

18. Evaluation of Simple Suspension Method for Erlotinib Dosing and Its Pharmacokinetic Profile in Patients with Non-Small Cell Lung Cancer

Author

Takada, Tetsuya, primary, Ikemi, Yasuaki, additional, Fukudo, Masahide, additional, Sugimoto, Mitsuhiro, additional, Ishibashi, Naoya, additional, Kobayashi, Masahiko, additional, Yano, Ikuko, additional, Kim, Young Hak, additional, Mishima, Michiaki, additional, Ashihara, Eishi, additional, and Matsubara, Kazuo, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results